Immunocore Holdings plc (IMCR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 97,964 | 93,881 | 80,248 | 75,400 |
| Research and development expense | 69,008 | 56,468 | 52,770 | 51,072 |
| Cost of revenue from sale of therapies | 1,040 | 831 | 448 | 1,707 |
| Selling, general and administrative expense | 42,791 | 40,198 | 35,532 | 38,638 |
| Loss from operations | -14,875 | -3,616 | -8,502 | -16,017 |
| Interest income | 4,271 | 4,176 | 5,960 | 6,239 |
| Interest expense | 3,045 | 3,025 | 4,290 | 4,277 |
| Foreign currency (loss) gain | -738 | 3,080 | 3,963 | -508 |
| Other income, net | 4,693 | 5,469 | 8,962 | 4,433 |
| Net loss before income taxes | -9,694 | 6,084 | 6,093 | -10,130 |
| Income tax expense | 606 | 1,061 | -2,643 | 1,486 |
| Net loss | -10,300 | 5,023 | 8,736 | -11,616 |
| Exchange differences on translation of foreign operations | 6,476 | 673 | 3,247 | 944 |
| Total comprehensive (loss) income | -3,824 | 5,696 | 11,983 | -10,672 |
| Basic net loss per share (in usd per share) | -0.2 | 0.1 | 0.17 | -0.23 |
| Basic weighted-average number of shares outstanding (in shares) | 50,294,205 | 50,086,684 | 50,021,939 | 50,014,086 |
| Diluted net loss per share (in usd per share) | -0.2 | 0.1 | 0.17 | -0.23 |
| Diluted weighted-average number of shares outstanding (in shares) | 50,294,205 | 51,949,798 | 52,808,434 | 50,014,086 |